{"public_id":"cl_343f9e860f5bd1fe9231526f758ca41c","status":"active","superseded_by_public_id":null,"corpus_id":24762552,"text":"Observed-to-expected analysis found significantly elevated bladder cancer risk in all subjects and in pravastatin users.","confidence":0.93,"paper":{"corpus_id":24762552,"title":"Pravastatin Use and the Five-year Incidence of Cancer in Coronary Heart Disease Patients: from the Prevention of Coronary Sclerosis Study","url":"https://sah.borca.ai/papers/24762552"},"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.93,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_46bb59dc0d6b22594c90b6c88135ec60","name":"observed/expected ratio","description":"A comparison of observed cancer counts to expected counts by site.","types":["statistical measure","comparison metric"],"url":"https://sah.borca.ai/concepts/co_46bb59dc0d6b22594c90b6c88135ec60"},{"public_id":"co_64aebaae7deb40a2df2f91f7e0a25685","name":"bladder cancer","description":"A cancer site analyzed in the observed-to-expected analysis.","types":["cancer site","outcome"],"url":"https://sah.borca.ai/concepts/co_64aebaae7deb40a2df2f91f7e0a25685"},{"public_id":"co_ee0d2eefe709f8b3b0f346e9cf24d220","name":"pravastatin use","description":"Exposure to the statin pravastatin during the follow-up period.","types":["drug exposure","intervention"],"url":"https://sah.borca.ai/concepts/co_ee0d2eefe709f8b3b0f346e9cf24d220"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_343f9e860f5bd1fe9231526f758ca41c"}